A significant chunk of Smith & Nephew‘s (FTSE:SN; NYSE:SNN) shareholders withheld their endorsement or voted outright against a $2.5 million "golden hello" for new CEO Olivier Bohuon after an advisory board recommended a veto.
About 30% of the British health care giant’s backer’s either voted against the company’s compensation report or abstained from voting, according to The Guardian.
"It is unclear how a golden hello benefits shareholders," proxy advisor Pirc said ahead of Smith & Nephew’s annual meeting, noting that cash bonuses neared 100% for top management even though SNN missed financial targets, according to the newspaper.
Sign up to get our free newsletters delivered straight to your inbox
About 8% of shareholders vetoed the pay plan outright, with another 22% deliberately abstaining, according to The Guardian.
Smith & Nephew posted profits of $279 million, or 16 cents per share, on sales of $1.12 billion for the 3 months ended Dec. 31, 2011. That’s a 3.7% addition to the top line, although profits were flat at a 0.4% gain, compared with profits of $278 million, or 21 cents per share, on sales of $1.07 billion during the same period in 2010.
For the full year, profits were $961 million, or 65 cents EPS, on sales of $4.27 billion, down 0.8% and up 7.8%, respectively, compared with profits of $969 million, or 69 cents EPS, on sales of $3.96 billion during 2010.
Smith & Nephew tapped Bohuon a year ago to replace David Illingworth. Last week the company named Baroness Virginia Bottomley of Nettlestone to its board of directors.
PhRMA taps Eli Lilly CEO Lechleiter for chairman
The Pharmaceutical Research & Manufacturers of America named Eli Lilly (NYSE:LLY) chairman, president & CEO John Lechleiter chairman. Read more
Response Biomedical names new CEO
Response Biomedical (TSE:RBM) named Jeffrey Purvin CEO effective May 1, replacing Dr. Peter Thompson as interim CEO; Thompson will stay on as chairman. Read more
From Medical Design & Outsourcing
- New results detail J&J Embotrap design’s first-pass performance in stroke patientsJohnson & Johnson (NYSE:JNJ) has released results for its Embotrap stent retrievers showing the next-generation design’s success in removing blood clots from ischemic stroke patients. Johnson & Johnson MedTech’s Cerenovus subsidiary tracked outcomes for 1,000 ischemic stroke patients who underwent mechanical thrombectomy procedures with Embotrap devices as a first-line therapy. “The positive preliminary findings of… […]
- Cardinal Health expands single-use device reprocessing facilityCardinal Health (NYSE:CAH) recently opened its expanded Sustainable Technologies facility in Riverview, Florida. The facility is now twice as large as before, at 100,000 square feet, said Dublin, Ohio-based Cardinal Health. The medical device manufacturer and distributor launched Sustainable Technologies in 2015 to collect, reprocess and recycle single-use devices in the U.S. Sustainable Technologies now… […]
- A new mechanically active adhesive fights muscle atrophyHarvard bioengineers have created a mechanically active adhesive that can prevent muscle wasting and support atrophy recovery. They call it MAGENTA, an acronym for mechanically active gel–elastomer–nitinol tissue adhesive. Researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences successfully tested… […]
- November 2022 Issue: 2022 Medical Device HandbookMedtronic, Abbott and ResMed see healthcare improving through ecosystems DermaSensor aims to expand access to accurate skin cancer detection How J&J’s Embotrap stent retriever thrombectomy treats ischemic strokes Design challenges to overcome when developing cardiac ablation devices How Medtronic designed the next generation of GI bleeding treatment Innovate together Medical devices have never been… […]
- Could minimally invasive neuromod tackle the opioid epidemic?Officials at Spark Biomedical and AcuityMD think their partnership could accelerate the commercialization of Spark’s potentially game-changing platform. Spark Biomedical develops a topical, minimally invasive medical device for alleviating opioid withdrawal symptoms. AcuityMD has a platform for helping medical device companies accelerate commercial access to their products. Together, they seek to provide a pathway to… […]
- BMP Medical appoints Michael Carignan as programs and engineering managerBMP Medical announced that it appointed Michael Carignan as its new programs and engineering manager. Carignan joins BMP Medical at its Sterling, Massachusetts plastic manufacturing hub facility. He brings with him more than 33 years of experience in the plastic manufacturing industry. Before BMP Medical, Carignan served as president of Wachusett Precision Tool for more… […]
- PTI Engineered Plastics receives MedAccred plastics accreditationPTI Engineered Plastics recently announced that MedAccred has recognized it for its commitment to continual improvement in medical device quality. The Macomb, Michigan–based company’s MedAccred accreditation follows a successful audit. MedAccred found that the medical device contract manufacturer demonstrated an ongoing commitment to quality by satisfying customer requirements and industry specifications. The nonprofit Performance Review… […]
- Millstone Medical Outsourcing buys MycoScienceMillstone Medical Outsourcing has purchased MycoScience, the companies said today. Fall River, Massachusetts-based Millstone said it closed the deal on Nov. 14. Terms were not disclosed. Willington, Connecticut-based MycoScience is an ISO 13485 certified contract manufacturing organization operating out of an FDA-registered facility. The company has more than three decades of experience in medical device… […]
- These 14 medical device inventions are the best, Time magazine saysFourteen medical devices ranging from patient monitoring to surgical robotics recently made it into Time magazine’s Best Inventions of 2022. For over 20 years, Time magazine has highlighted the 100 most impactful devices and ideas around the world. The list is compiled through nominations from the publication’s editors and global correspondents, with special attention to… […]
- Why Affera’s cardiac ablation technology is worth $1B to MedtronicAffera started in 2014 with a simple goal that paid off when Medtronic (NYSE:MDT) bought the company for up to $1 billion this year. Achieving that goal, however, took some unconventional and sometimes difficult design choices, Affera founder and CEO Doron Harlev said. Newton, Massachusetts–based Affera’s system diagnoses, maps and treats heart arrhythmias with ablation.… […]
- Viant expands Design & Development West Center of Excellence in CaliforniaViant today said it has completed the expansion of its Design & Development West Center of Excellence in Fremont, California. The facility’s footprint is now 67% larger, totaling 25,000 sf² across two buildings co-located with the company’s complex molding and assembly facility. The expansion triples the amount of ISO 8 and ISO 7 cleanroom space… […]
